
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 11, 2017

RENNOVA HEALTH, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-35141
(Commission File Number)

68-0370244
(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida
(Address of Principal Executive Offices)

33401
(Zip Code)

(561) 855-1626
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Attached to this report as Exhibit 99.1 is a presentation that Rennova Health, Inc. (the “Company”) may present to investors, analysts and others. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibit No.	Exhibit Description
99.1	Presentation slides.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 11, 2017

RENNOVA HEALTH, INC.

By: /s/ Seamus Lagan
Seamus Lagan
Chief Executive Officer
(principal executive officer)

EXHIBIT INDEX

Exhibit No.	Exhibit Description
99.1	Presentation slides.

July 2017

RennovaHealth

Solutions Driven By Innovation

Nasdaq:

Common stock RNVA

Warrants (July 2021) RNVAZ

Diagnostics and Supportive Software
Solutions to Healthcare Providers



Forward Looking Statements and Non-GAAP Information


This presentation includes forward-looking statements about Rennova Health's anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Rennova Health with the Securities and Exchange Commission. Rennova Health undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances, except to the extent required by applicable law or regulation.

Note: This presentation includes certain "Non-GAAP" financial measures as defined by SEC rules. As required by the SEC, we have provided a reconciliation of those measures to the most directly comparable GAAP measures on the Regulation G slide included as slide 13 of this presentation. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, reported GAAP results.

Healthcare is Being Transformed



We have the technology



We have the science



We have the expertise



We are Rennova Health

Key Investment Highlights


- Five-year history of operations in clinical laboratory space
 - Toxicology
 - Clinical
 - Genetic testing including pharmacogenomics and oncology
- Three years in software development for the medical sector
 - Proprietary lab ordering and reporting
 - Lab information systems
 - Electronic Health Records
 - Medical billing software (Licensed)
- Capital investment in our Clinical Labs of approximately \$8M
 - Own Labs in Florida, New Mexico, New Jersey, California and Connecticut
 - Adequate capacity to facilitate growth without additional investment
- Investment in our Software assets of approximately \$12M
- We operate in a very sizable and well established market place and offer products and services for which there is an increasing demand
- We have a focused strategy for growth expanding from an historical concentration on servicing the substance abuse sector in Florida to a national and diverse marketplace to include the substance abuse and pain management sectors.
- We have;
 - A capable, experienced management team
 - Value added software products launched to create a sustainable relationship with contracted, recurring revenue
- We have significant opportunity for growth of diagnostics revenues in 2017 and beyond leveraging our capability, our compliance record, expanded national footprint, our expanding menu of diagnostics and a rapidly increasing number of in-network contracts with a number of payers and secondary networks nationwide

Rennova Offers a Single Source Solution for Medical Providers

- The diagnostics sector has changed dramatically in the last few years
- Paper records and faxes meant different vendors to a medical provider could function side by side without communication
- Electronic platforms and integration have created a need for providers of solutions to communicate efficiently, accurately, automatically and fast
- Medical providers need more than just diagnostics; they need an increasing number of integrated and interoperable solutions to enable their business to function
- Compliance needs have increased with an ever more demanding regulatory and payer environment
- The need to have contracts with insurance companies and other payers to ensure receipt of payment for services is increasing

Rennova has positioned itself to maintain a sustainable long term relationship with medical providers by providing a number of essential products and services, creating efficiencies for the provider and benefiting from additional contracted and recurring revenue for the provision of these services and products

Rennova Offers a Single Source Solution for Medical Providers



Recent Developments

Clinical Laboratory Operations Segment

- Transitioned from focus on toxicology to expanded menu of clinical diagnostics
- Acquired CollabRx and Genomas for their technology in the oncology interpretation market and the pharmacogenomics testing sector
- Hospital acquisition completed in January 2017 (needed service)
 - Opening and launch planned for August 2017
- We have invested in compliance and have an unblemished history
- We now possess Medicaid Licenses in 28 States
- We entered into fourteen new payer in-network contracts in 2016, bringing our total payer contracts at this time to twenty
- Recently secured National Payer contract that will be effective from Sept 1st 2017
- We have expanded our business to include a number of ACO contracted doctor groups and a CRO (Clinical research organization)

Recent Developments

Supportive Software Solutions Segment

- Our integrated software solution creates a much more sustainable relationship with our customers
 - EHR product launched in substance abuse sector last quarter 2015

Revenue Cycle Management

- We launched a specialized division to provide medical billing services to substance abuse facilities in 3rd quarter 2016
- Expanding this division to service many other specialties
- We believe our EHR and software integration capabilities give us an advantage in this sector
- Intend to add automated charge capture to our features

Corporate and Company-Wide

- Successfully completed the integration of three Florida based Labs into one
- Executed reductions in operating expenses during the second and third quarter of 2016
- Have started to recover customers and volume of testing after what has been a difficult year to compete with fraudulent practices in our core business sector
- Expect higher revenue and reimbursement in 2017 for many of our core diagnostics based on recently announced increases by CMS
- Secured significant Capital to deliver on our business objectives

Our Target Markets

Drug and Alcohol Rehabilitation

- Total Market Size – estimated at \$35 Billion*
- Large and growing number of facilities in a fragmented market
- Between 14,500 to 16,700 outpatient clinics*

Market growth from high demand:

- Over 23 million Americans are addicted to alcohol and other drugs**
- The number of Americans in addiction treatment ranges from 2.5 million to 4.1 million***
- 3 to 5 million people who have a diagnostic addiction disorder warranting treatment will gain coverage through healthcare reform****
- Six states currently require some form of urine toxicology testing for the treatment of substance abuse or opioid therapy, and at least nine other states recommend such testing in their medical treatment guidelines

Pain Management Sector

- Total Market Size – estimated at \$2-\$4 Billion*****
- Large and growing number of clinics in a fragmented market
- Private clinics in the U.S. estimated between 1,500 and 2,500*****
- More than 6,800 doctors specialize in pain management and more than 600,000 doctors are licensed to prescribe pain medication*****

Market growth from high demand:

- Chronic pain affects an estimated 100 million Americans, or one-third of the U.S. population*****
- Approximately 25 million people experience moderate to severe chronic pain with significant pain-related activity limitations and diminished quality of life*****
- Between 5 to 8 million people use opioids for long-term pain management*****
- In 2015, U.S. providers wrote 204 million prescriptions for opioid painkillers*****

Market Drivers

Lab Services Drivers

- Secular growth
- Compliance

Value-added services


- Efficiency
- Cost
- Revenue cycle management

Sources:

*IBIS World.
 **The National Council on Alcoholism and Drug Dependency.
 ***SAMHSA.
 ****National Association of Alcoholism and Drug Abuse Counselors
 *****The U.S. Addiction Rehab Market, Bharat Publication.
 *****NIH.
 *****CDC and Pain Physician Publication.

***** U.S. Department of Justice and Federal Trade Commission.
 *Horizontal Merger Guidelines, August 2012.
 ***** National Institutes of Health
 *Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain, September 2014.
 ***** Champion Pain Care Corp
 10-K filing and the U.S. Addiction Rehab Market, Bharat Publication


Rennova Health Licensing Map



Our Payers

- **Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015**
 - Applied for Medicaid Licenses in 34 States
 - We possess Medicaid Licenses in 28 States
- **Current Third Party Insurance Payer Contracts**
 - Blue Shield of California
 - Coventry (National Contract)
 - Corvel
 - Multiplan
 - PrimeHealth
 - FedMed
 - HealthSmart
 - America's Choice Provider Network
 - Tricare – South (Humana Military)
 - Health Net Services (Tricare North)
 - Three Rivers Provider Network
 - Fortified Provider Network
 - Galaxy Health Network
 - Passport Health Network (MCO Kentucky)
 - Wellcare (MCO Kentucky)
 - Stratose
 - Tricare – West (UHC)
 - Community Care Plan (MCO Florida)
 - Coventry Healthcare of Virginia (MCO Virginia)
 - McLaren Health Plan (MCO Michigan)

History in Numbers




Select Income Statement Items

<i>(in thousands)</i>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
GAAP Net Revenue	\$ 41,889	\$ 57,928	\$ 18,393	\$ 5,245
Reserve for Aged Accounts Receivable	-	1,501	19,494	1,000
Adjusted Revenues	<u>\$ 41,889</u>	<u>\$ 59,429</u>	<u>\$ 37,887</u>	<u>\$ 6,245</u>
 GAAP Pretax Income (Loss)	 \$ 13,829	 \$ 15,382	 \$ (44,991)	 \$ (32,400)
Depreciation and Amortization	408	1,500	2,750	3,046
Interest Expense	475	514	2,690	6,300
Impairment of Goodwill and Intangibles	-	-	20,143	1,038
Loss (Gain) on Change in Derivative Values	-	-	(2,328)	(5,400)
Stock Compensation Expense	63	852	3,628	1,200
Reserve for Aged Accounts Receivable	-	1,501	19,494	1,000
Adjusted EBITDA	<u>\$ 14,775</u>	<u>\$ 19,749</u>	<u>\$ 1,386</u>	<u>\$ (25,216)</u>



Strategy



The Long Term Strategy

Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders

How?

Build from a toxicology-focused company to:

1. A significant and diverse diagnostics business including the provision of “needed services” from ownership of hospitals and Dr’s practices
2. Offering supportive software solutions that add value by generating sustainable customer relationships and revenue and then leveraging the integration and analytic capabilities to quickly assess value of receivables with an ambition to provide financial services
3. Exploring and developing new opportunities to improve provider and patient experiences and outcomes, including for diabetes and cancer diagnostics and products that are provided directly to patients.

Remain proactive to the needs of patients and medical providers.

2017 Goals

- **Strengthen Core Diagnostic Business**
 - Plan to open our 1st hospital
 - Continue to capitalize on the disruption in toxicology sector
 - Increase Clinical testing
 - Grow Pharmacogenomics testing with Genomas
 - Launch DTC (Direct to Consumer) testing
 - Consider opportunities for acquisition of additional hospital and Dr's practices
- **Accelerate Growth and/or Launch:**
 - Software product sales
 - Medical Billing services as an integrated service
 - Interpretation and decision support in cancer diagnostics directly to doctors and public
 - Investigate opportunities for cancer diagnostics leveraging Genomas capabilities
 - Investigate opportunities for spin out of Genetic division and Software division



Clinical testing with advanced analyzers



Our goal in numbers

- **We believe that we can achieve the following revenues for 2018**

- \$600K per month for toxicology and clinical diagnostics
- \$400K per month for software and RCM related revenue
- \$1M per month from our hospital in TN

Subject to acquisition

- \$800K per month from Dr's practices
- \$1M per month from acquisition of additional hospital

Potential revenue of \$3.8M per month or \$45.6M per annum



Clinical testing with advanced analyzers



Rennova Management

Seamus Lagan CEO	<ul style="list-style-type: none"> • 20 years experience in the restructuring, development and management of startup and small companies
Victoria Nemerson, Esq. General Counsel	<ul style="list-style-type: none"> • 25 years experience as a compliance and healthcare attorney
Scott Jenkins CEO of Genetic Testing Division	<ul style="list-style-type: none"> • Prior CEO Positions at Alchemist Ventures, Certainty Health, BioSign; Senior Executive positions at Applied Biosystems, Dell, IBM, Apple, Sandoz (Novartis)
Samuel Mitchell CEO of Software & IT Division	<ul style="list-style-type: none"> • 20 years experience in the healthcare industry holding executive positions in multi speciality medical groups and a full service hospital. Has Masters degree in Business Administration and Health Administration
Tony Taylor CEO of Hospital Division	<ul style="list-style-type: none"> • 30 years in healthcare administration including CEO of large hospital group
Al Lechner EVP of Sales, Software Solutions	<ul style="list-style-type: none"> • 30 years with GE Healthcare • Responsible for healthcare technology & software sales
Sebastien Sainsbury Investor & Public Relations	<ul style="list-style-type: none"> • Banking and wealth management and 10 years on the Board of AIG International
Karen Taylor Director, Human Resources	<ul style="list-style-type: none"> • Executive Human Resources professional with healthcare experience and diverse public company experience

Board of Directors (July 2017)

Seamus Lagan CEO	<ul style="list-style-type: none">• 20 years experience in the restructuring, development and management of startup and small companies• Founder, investor and shareholder
Christopher Diamantis Director	<ul style="list-style-type: none">• Chairman and CEO of Integrated Financial Settlements, Inc., a structured settlement consulting firm.
Trevor Langley Director	<ul style="list-style-type: none">• 20 years experience in the structuring and financing of small and micro-cap publicly traded companies
Dr. Kamran Ajami Director	<ul style="list-style-type: none">• Medical Director at Westside Regional Hospital & Plantation General Hospital's pathology department. Dr. Ajami attended Harvard Medical School and is a surgical pathologist with subspecialties in Gyn, Breast and Neuro-pathology. Dr. Ajami serves as the CEO of American Cytopathology Associates, PA, which supplies medical directors for laboratories.

Capitalization July 11th 2017

Capitalization Table

	11-Jul-17	
		Common Shares
		Issuable upon Exercise/ Conversion
Common Stock	14,473,360	14,473,360
Series G Preferred Stock	215	15,926
Series H Preferred Stock	60	153,847
Convertible Debentures	12,943,674.00	33,188,907
warrants with an exercise price of \$0.39 (exercisable as of Dec 2nd 2017)		1,500,000
Warrants with an exercise price of \$1.56 per share, subject to further adjustment		29,184,193
Warrants with an exercise price of \$3.375 per share		228,709
Warrants with an exercise price of \$13.50 per share		1,070,940
Warrants with an exercise price of \$.30 per share		11,820
Stock Options (weighted average exercise price of \$129.43 per share)		709,025
		<u>80,536,727</u>

Key Investment Highlights

- Five-year history of operations in clinical laboratory space
 - Toxicology
 - Clinical
 - Genetic testing including pharmacogenomics and oncology
- Three years in software development for the medical sector
 - Proprietary lab ordering and reporting
 - Lab information systems
 - Electronic Health Records
 - Medical billing software (Licensed)
- Capital investment in our Clinical Labs of approximately \$8M
 - Own Labs in Florida, New Mexico, New Jersey, California and Connecticut
 - Adequate capacity to facilitate growth without additional investment
- Investment in our Software assets of approximately \$12M
- We operate in a very sizable and well established market place and offer products and services for which there is an increasing demand
- We have a focused strategy for growth expanding from an historical concentration on servicing the substance abuse sector in Florida to a national and diverse marketplace to include the substance abuse and pain management sectors.
- We have;
 - A capable, experienced management team
 - Value added software products launched to create a sustainable relationship with contracted, recurring revenue
- We have significant opportunity for growth of diagnostics revenues in 2017 and beyond leveraging our capability, our compliance record, expanded national footprint, our expanding menu of diagnostics and a rapidly increasing number of in-network contracts with a number of payers and secondary networks nationwide